• Topical Corticosteroid
    • Proactive Maintenance...
    • Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Topical corticosteroid,Mometasone furoate,Vulvar lichen,0·1 ointment,Topical corticosteroids,Cold cream,Proactive maintenance,Vulvar lichen sclerosus.

      Key People For Topical Corticosteroid

      Top KOLs in the world
      Hywel C G Williams
      atopic eczema cochrane skin basal cell carcinoma
      Howard Ira Maibach
      contact dermatitis percutaneous absorption human skin
      Thomas Ruzicka
      atopic dermatitis lupus erythematosus pyoderma gangrenosum
      Jon M Hanifin
      atopic dermatitis eczema herpeticum histamine release
      Amy S Paller
      atopic dermatitis pediatric patients epidermolysis bullosa
      Steven Richard Feldman
      united states atopic dermatitis psoriasis patients

      Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study


      BACKGROUND: The chronic and relapsing nature of vulvar lichen sclerosus (VLS) represents a challenge for its long-term management after an effective treatment with topical corticosteroids.

      OBJECTIVES: To assess the effectiveness of proactive, twice-weekly application of mometasone furoate 0·1% ointment, compared with daily topical vitamin E or cold cream, in keeping VLS in remission and reducing the risk of relapse after 3 months of treatment with topical corticosteroid.

      METHODS: In total, 27 patients affected with VLS were enrolled into a 12-week active treatment phase (AP) with topical mometasone furoate 0·1% ointment once daily. Those who achieved disease remission entered a 52-week maintenance phase (MP) in which patients were randomized to apply either mometasone furoate 0·1% ointment twice weekly, a cold cream once daily or topical vitamin E once daily. The primary efficacy parameters were the relapse rate and the mean time to relapse.

      RESULTS: Twenty-five patients considered to have been completely or almost completely healed after the AP entered the MP. By the end of the 52-week MP, 10 patients (40%) experienced a relapse: five in the vitamin E group (56%) and five in the cold cream group (62%), while no patient in the mometasone furoate 0·1% ointment group had a relapse. The occurrence of VLS relapse for patients in therapy with both vitamin E and cold cream was significantly higher than for those in proactive therapy with topical corticosteroid. The median time to relapse was the same (21·6 weeks) for the vitamin E and the emollient groups.

      CONCLUSIONS: Once VLS has been stabilized with topical corticosteroids, twice-weekly proactive application of mometasone furoate 0·1% ointment over 56 weeks was found to be an effective and safe therapy option in maintaining VLS remission and in preventing the occurrence of relapse.

      Sign-in to see all concepts, it's free!


    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.